Brief: FDA Approves IND Submission Allowing ABVC Biopharma To Proceed With Clinical Study Of Abv-1519 To Treat Non-Small Cell Lung Cancer
05/01/2023 15:08
Jan 5 (Reuters) - ABVC Biopharma Inc ABVC.O :
* FDA APPROVES IND SUBMISSION ALLOWING ABVC BIOPHARMA TO
PROCEED
WITH CLINICAL STUDY OF ABV-1519 FOR TREATMENT OF NON-SMALL CELL
LUNG CANCER
Source text for Eikon: ID:nGNX5Js99x
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon